Facebook
Twitter
Telegram
Report an ErrorHepion Pharmaceuticals Balance Sheet 2011-2024 | HEPA
Annual Balance Sheet Hepion Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-91 M | -40.3 M | -13.1 M | -1.39 M | -13 M | -7.39 M | -4.56 M | -1.82 M | -86.7 K | - | - | ||
Long Term Debt |
93.1 K | - | 50.3 K | 177 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
116 K | 53.6 K | 267 K | 280 K | 267 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 177 K | 3 M | 3.36 M | 6.38 M | 6.71 M | - | 4.48 M | - | - | - |
Total Current Liabilities |
5.29 M | 7.89 M | 8.21 M | 4.66 M | 1.25 M | 2.85 M | 2.6 M | 5.08 M | 1.94 M | 459 K | - | - | - |
Total Liabilities |
10.8 M | 10.4 M | 10.6 M | 8.12 M | 4.25 M | 6.21 M | 9.33 M | 11.8 M | 1.94 M | 4.93 M | 227 K | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-225 M | -176 M | -134 M | - | -83.2 M | -76.5 M | -59.5 M | -44.6 M | -27.6 M | -5.42 M | -140 K | - | - |
Total Assets |
18.1 M | 60.2 M | 104 M | 48.6 M | 20.4 M | 8.19 M | 18.4 M | 13.1 M | 5.38 M | 2 M | 86.7 K | - | - |
Cash and Cash Equivalents |
14.8 M | 51.2 M | 91.3 M | 40.7 M | 13.9 M | 2.83 M | 5.95 M | 7.4 M | 4.56 M | 1.82 M | 86.7 K | - | - |
Book Value |
7.28 M | 49.9 M | 93 M | 40.5 M | 16.2 M | 1.98 M | 9.06 M | 1.32 M | 3.44 M | -2.93 M | -140 K | - | - |
Total Shareholders Equity |
7.28 M | 49.9 M | 93 M | 40.5 M | 15.6 M | 1.98 M | 3.7 M | 1.32 M | 3.44 M | -2.93 M | -140 K | - | - |
All numbers in USD currency
Quarterly Balance Sheet Hepion Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
41.2 K | 93.1 K | 129 K | - | - | - | - | - | - | 50.3 K | 99.1 K | 167 K | 300 K | 296 K | 296 K | 296 K | 296 K | 541 K | 541 K | 541 K | 541 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.47 M | 10.8 M | 8.84 M | 10.1 M | 12.3 M | 10.4 M | 10.4 M | 16.2 M | 9.22 M | 10.6 M | 8.96 M | 9.03 M | 6.18 M | 8.12 M | 8.12 M | 8.12 M | 8.12 M | 4.99 M | 4.99 M | 4.25 M | 4.25 M | 6.21 M | 6.21 M | 6.21 M | 6.21 M | 7.55 M | 7.55 M | 7.55 M | 7.55 M | 10.2 M | 11.8 M | 11.8 M | 11.8 M | 5.66 M | 4.22 M | 1.94 M | 1.94 M | 361 K | 465 K | 4.93 M | 4.93 M | - | 227 K | 227 K | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-227 M | -225 M | -214 M | -203 M | -189 M | -176 M | -169 M | -160 M | -140 M | -134 M | -127 M | -118 M | -110 M | -104 M | -104 M | -104 M | -104 M | -83.8 M | -83.8 M | -83.2 M | -83.2 M | -76.7 M | -76.5 M | -76.5 M | -76.5 M | -67 M | -67 M | -67 M | -67 M | -53.9 M | -49.4 M | -44.6 M | -44.6 M | -35.5 M | -32.5 M | -27.6 M | -27.6 M | -14.8 M | -6.89 M | -5.42 M | -5.42 M | - | - | -140 K | - | - | - | - | - | - | - | - | - |
Total Assets |
16 M | 18.1 M | 25 M | 36.5 M | 49.5 M | 60.2 M | 69.7 M | 83.6 M | 95.9 M | 104 M | 112 M | 120 M | 124 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 20.6 M | 20.6 M | 20.4 M | 20.4 M | 8.19 M | 8.19 M | 8.19 M | 8.19 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 16.1 M | 8.82 M | 13.1 M | 13.1 M | 10.6 M | 2.85 M | 5.38 M | 5.38 M | 8.96 M | 1 M | 2 M | 2 M | 8.83 K | 76 K | 86.7 K | 86.7 K | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
13.1 M | 14.8 M | 19.3 M | 30.5 M | 43 M | 51.2 M | 59.1 M | 71.7 M | 79.2 M | 91.3 M | 98.7 M | 110 M | 115 M | 40.7 M | 40.7 M | 40.7 M | 40.7 M | 13.9 M | 14.9 M | 17.1 M | 1.68 M | 2.83 M | 2.83 M | 2.83 M | 2.83 M | 5.95 M | 5.95 M | 13 M | 5.95 M | 10.6 M | 3.03 M | 7.4 M | 3.03 M | 9.83 M | 1.79 M | 9.83 M | 1.79 M | 8.79 M | 735 K | 8.79 M | 735 K | 3.28 K | 76 K | 3.28 K | 76 K | - | - | - | - | - | - | - | - |
Book Value |
7.52 M | 7.28 M | 16.2 M | 26.4 M | 37.2 M | 49.9 M | 59.3 M | 67.3 M | 86.6 M | 93 M | 103 M | 111 M | 118 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 15.6 M | 15.6 M | 16.2 M | 16.2 M | 1.98 M | 1.98 M | 1.98 M | 1.98 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.88 M | -3 M | 1.32 M | 1.32 M | 4.98 M | -1.36 M | 3.44 M | 3.44 M | 8.6 M | 540 K | -2.93 M | -2.93 M | 8.83 K | -151 K | -140 K | 86.7 K | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
7.52 M | 7.28 M | 16.2 M | 26.4 M | 37.2 M | 49.9 M | 59.3 M | 67.3 M | 86.6 M | 93 M | 103 M | 111 M | 118 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 15.6 M | 15.6 M | 16.2 M | 16.2 M | 1.72 M | 1.98 M | 1.98 M | 1.98 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.88 M | -3 M | 1.32 M | 1.32 M | 4.98 M | -1.36 M | 3.44 M | 3.44 M | 8.6 M | 540 K | -2.93 M | -2.93 M | -490 K | -323 K | -140 K | -140 K | - | - | - | - | - | - | - | - |
All numbers in USD currency